**Indication** | Heart failure  
---|---
**INN** | Digoxin  
**Medicine type** | Chemical agent  
**List type** | Core (EML)  
| Complementary (EMLc)  
**Formulations** | Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule (EMLc)  
| Oral > Liquid: 50 µg per mL  
| Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg (EMLc)  
**EML status history** | First added in 1977 (TRS 615)  
| Changed in 1979 (TRS 641)  
| Changed in 2007 (TRS 950)  
| Changed in 2023 (TRS 1049)  
**Sex** | All  
**Age** | Also recommended for children  
**Therapeutic alternatives** | The recommendation is for this specific medicine  
**Patent information** | Patents have expired in most jurisdictions  
| Read more about patents.  
**Wikipedia** | Digoxin  
**DrugBank** | Digoxin  

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for digoxin on the EMLc be transferred from the core to the complementary list, and the addition of new strength dosage forms (injection 100 mcg/mL and tablet 125 mcg) to the EMLc.